To assess if these differentially regulated signaling pathways are uniquely associated with KRAS mutation, we selected a cohort of KRAS wild type (WT) CRC cases (cohort 3), composed of 6 HES1 (+) and 6 HES1 (−) samples. This evidence concerns the gene HES1 and colorectal carcinoma.